Feasibility of international trials of rare epithelial ovarian cancers based on trends in the United States and Asia (163)

Abstract

Objectives: To investigate the feasibility of international clinical trials in rare ovarian cancers by first studying the incidence and trends of the rare histologic subtypes in the United States (US) and Asia. Methods: Data were obtained from the United States Cancer Statistics (USCS) Public Use Databases and Taiwan Cancer Registry of Taiwan Health and Welfare Data Center (HWDC) for a diagnosis of ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, or carcinosarcoma between 2001 to 2017. SEER*Stat 8.3.9, Joinpoint regression program 4.8.0.1, and Excel were used to calculate the incidence and trends. Results: In 2017, the incidence of ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, or carcinosarcoma was 0.81, 0.51, 0.47, or 0.25 per 100,000 in the US, and 1.58, 1.17, 1.08, or 0.15 per 100,000 in Asia, respectively. Over the last 18 years, the average annual percent change (AAPC) in clear cell carcinoma did not change in the US and increased by 6.2% in Asia. The AAPC for ovarian endometrioid carcinoma decreased by 2.7% in the US and increased by 2.9% in Asia. Although the rate of carcinosarcoma is increasing in both the US and Asia, it is 16-fold higher in Asia compared with the US, with an AAPC for ovarian carcinosarcoma of 6.4% in Asia versus 0.4% in the US. The rate of ovarian mucinous carcinoma decreased in both the US and Asia with an AAPC of 2.0% versus 0.9%, respectively. Conclusions: The AAPC of ovarian clear cell carcinoma, endometrioid carcinoma, and carcinosarcoma is increasing at higher rates in Asia than in the US, providing justification to utilize global recruitment strategies for clinical trial investigational treatments and interventions in rare ovarian cancers. Objectives: To investigate the feasibility of international clinical trials in rare ovarian cancers by first studying the incidence and trends of the rare histologic subtypes in the United States (US) and Asia. Methods: Data were obtained from the United States Cancer Statistics (USCS) Public Use Databases and Taiwan Cancer Registry of Taiwan Health and Welfare Data Center (HWDC) for a diagnosis of ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, or carcinosarcoma between 2001 to 2017. SEER*Stat 8.3.9, Joinpoint regression program 4.8.0.1, and Excel were used to calculate the incidence and trends. Results: In 2017, the incidence of ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, or carcinosarcoma was 0.81, 0.51, 0.47, or 0.25 per 100,000 in the US, and 1.58, 1.17, 1.08, or 0.15 per 100,000 in Asia, respectively. Over the last 18 years, the average annual percent change (AAPC) in clear cell carcinoma did not change in the US and increased by 6.2% in Asia. The AAPC for ovarian endometrioid carcinoma decreased by 2.7% in the US and increased by 2.9% in Asia. Although the rate of carcinosarcoma is increasing in both the US and Asia, it is 16-fold higher in Asia compared with the US, with an AAPC for ovarian carcinosarcoma of 6.4% in Asia versus 0.4% in the US. The rate of ovarian mucinous carcinoma decreased in both the US and Asia with an AAPC of 2.0% versus 0.9%, respectively. Conclusions: The AAPC of ovarian clear cell carcinoma, endometrioid carcinoma, and carcinosarcoma is increasing at higher rates in Asia than in the US, providing justification to utilize global recruitment strategies for clinical trial investigational treatments and interventions in rare ovarian cancers.